Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.

Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.

Chronic hepatitis C virus infections (HCV) cause a significant public health burden. Introduction of telaprevir (TVR) and boceprevir (BOC) has increased sustained virologic response rates (SVR) in genotype 1 patients but were accompanied by higher treatment costs and more side effects. Aim of the st...

Full description

Bibliographic Details
Main Authors: Jona T Stahmeyer, Siegbert Rossol, Florian Bert, Klaus H W Böker, Harald-Robert Bruch, Christoph Eisenbach, Ralph Link, Christine John, Stefan Mauss, Renate Heyne, Eckart Schott, Heike Pfeiffer-Vornkahl, Dietrich Hüppe, Christian Krauth
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4964984?pdf=render

Internet

http://europepmc.org/articles/PMC4964984?pdf=render

Similar Items